Key Takeaways
- Gilead finalized its $7.8 billion Arcellx purchase on April 28, 2026, securing complete rights to anito-cel, a promising CAR T-cell treatment for multiple myeloma.
- The stock is revisiting an 11-year cup pattern breakout support level at $123.47, with one market watcher forecasting $173 by year’s end — representing 35% upside.
- GILD shares are off 8% this month but remain up 22% year-over-year; current trading price hovers near $128.
- Technical indicators show GILD’s RSI at 27, marking the most oversold reading in over a year, while the 200-day moving average provides nearby support.
- The transaction will reduce both GAAP and non-GAAP 2026 diluted earnings per share by $5.57–$5.67, though projections show it becoming earnings-accretive starting in 2028, contingent on regulatory approval.
Gilead Sciences finalized its Arcellx takeover on April 28, delivering $115 cash per share alongside a conditional value right worth $5 per share. The complete implied equity valuation at closure reached roughly $7.8 billion.
This transaction grants Gilead complete control over anitocabtagene autoleucel, commonly known as anito-cel, an experimental BCMA-targeted CAR T-cell treatment designed for multiple myeloma patients. Before this acquisition, the two companies maintained a collaborative partnership through Kite, which serves as Gilead’s cellular therapy division.
With Arcellx now fully integrated, Gilead no longer faces future profit-sharing arrangements, milestone payments, or royalty commitments. This strategic shift empowers the pharmaceutical giant to accelerate both development timelines and commercial launch strategies.
The $5 contingent value right becomes executable only when worldwide net revenues for anito-cel reach a minimum threshold of $6 billion between product launch and the close of 2029. While this represents a substantial target, it demonstrates strong belief in the treatment’s market viability.
Cindy Perettie, who leads Gilead’s Kite division, emphasized that priorities now shift toward “executing with speed and discipline” while preparing to deliver anito-cel to patients. The Arcellx workforce and its proprietary D-Domain BCMA binder platform will merge into Kite’s existing manufacturing capabilities and regulatory framework.
Regarding financial implications, this acquisition will decrease Gilead’s GAAP and non-GAAP 2026 diluted earnings per share by $5.57 to $5.67. When acquired in-process research and development costs are excluded, the transaction should produce modest dilution throughout 2026 and 2027, transitioning to accretion beginning in 2028 — provided anito-cel receives FDA clearance.
Arcellx shares will exit the Nasdaq Global Select Market once the merger formalities conclude.
Chart Analysis
From a technical perspective, GILD occupies a compelling position. Shares are challenging an 11-year cup formation breakout at the $123.47 pivot point — a configuration tracing back to bearish candlestick formations during June and July 2015.
Extended-duration breakouts historically demonstrate elevated success probabilities, rendering this support retest particularly noteworthy. The stock’s RSI has plummeted to 27, marking its lowest reading in no less than twelve months, indicating deeply oversold territory. The 200-day simple moving average sits close by and has provided solid support during both May and October of the previous year.
GILD has posted losses in eight out of the past ten weeks, with April alone showing an 8% decline. Notably, both March and April’s downward movements occurred on subdued trading volume, which certain chart analysts interpret as a favorable signal.
Industry Landscape
The SPDR S&P Biotech ETF has climbed 9% throughout 2026, defying weakness across the wider healthcare space, which has fallen 7% and ranks as the poorest-performing among the 11 primary S&P sectors. The iShares Biotechnology ETF, which counts Gilead as its top position at approximately 8% of total holdings, has delivered less than 1% returns year to date.
GILD itself shows a 4% gain for the current year and maintains a 22% advance over the trailing twelve months despite recent weakness. One chart analyst has established a $173 price objective for year-end, suggesting 35% appreciation from present levels around $128. The optimistic outlook remains intact provided shares maintain position above $118.
Gilead wrapped up its tender offer for Arcellx on April 28, with submitted shares accounting for roughly 77.2% of Arcellx’s total outstanding equity.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
